Denali Therapeutics Inc. (NASDAQ:DNLI) Director Steve E. Krognes Sells 688 Shares

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Steve E. Krognes sold 688 shares of the company’s stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $21.79, for a total transaction of $14,991.52. Following the transaction, the director now owns 52,620 shares in the company, valued at approximately $1,146,589.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock opened at $21.30 on Thursday. The business has a 50-day moving average price of $19.80 and a 200-day moving average price of $19.28. Denali Therapeutics Inc. has a twelve month low of $14.56 and a twelve month high of $30.79.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.01. During the same period in the previous year, the business posted ($0.80) earnings per share. Sell-side analysts expect that Denali Therapeutics Inc. will post -2.78 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $95.00 target price on shares of Denali Therapeutics in a report on Wednesday, May 8th. Stifel Nicolaus decreased their target price on Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a report on Wednesday, May 8th. Wedbush decreased their target price on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, May 8th. Finally, UBS Group decreased their target price on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, April 9th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $40.22.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in DNLI. Wellington Management Group LLP lifted its stake in Denali Therapeutics by 3.6% in the third quarter. Wellington Management Group LLP now owns 7,288,960 shares of the company’s stock worth $150,371,000 after purchasing an additional 250,784 shares during the last quarter. Edmond DE Rothschild Holding S.A. lifted its stake in Denali Therapeutics by 65.9% in the fourth quarter. Edmond DE Rothschild Holding S.A. now owns 165,680 shares of the company’s stock worth $3,555,000 after purchasing an additional 65,800 shares during the last quarter. Pathway Capital Management LP bought a new stake in Denali Therapeutics in the fourth quarter worth about $1,490,000. Gotham Asset Management LLC bought a new stake in Denali Therapeutics in the third quarter worth about $400,000. Finally, Braidwell LP bought a new stake in Denali Therapeutics in the fourth quarter worth about $9,910,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.